Glioma Cell Invasion: Regulation of Metalloproteinase Activity by TGF-β
暂无分享,去创建一个
[1] D. Mercola,et al. The Transcription Factor EGR-1 Directly Transactivates the Fibronectin Gene and Enhances Attachment of Human Glioblastoma Cell Line U251* , 2000, The Journal of Biological Chemistry.
[2] M. Martin,et al. TGF-beta1 and radiation fibrosis: a master switch and a specific therapeutic target? , 2000, International journal of radiation oncology, biology, physics.
[3] J. Massagué. TGF-beta signal transduction. , 1998, Annual review of biochemistry.
[4] Y. Maehara,et al. Role of transforming growth factor-beta 1 in invasion and metastasis in gastric carcinoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] J. Tonn,et al. Interactions of glioma cells and extracellular matrix , 2005, Journal of Neuro-Oncology.
[6] H. Lodish,et al. Role of transforming growth factor beta in human disease. , 2000, The New England journal of medicine.
[7] J. Furuyama,et al. Expressions of matrilysin and stromelysin in human glioma cells. , 1993, Biochemical and biophysical research communications.
[8] D. Rifkin,et al. Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor-beta 1-like molecule by plasmin during co-culture , 1989, The Journal of cell biology.
[9] M. Hasegawa,et al. Transforming Growth Factor‐β1 Stimulates Contraction of Human Glioblastoma Cell‐Mediated Collagen Lattice through Enhanced α2 Integrin Expression , 2000 .
[10] M. Nakanishi,et al. Transforming growth factor-beta1 stimulates contraction of human glioblastoma cell-mediated collagen lattice through enhanced alpha2 integrin expression. , 2000, Journal of neuropathology and experimental neurology.
[11] H. Moses,et al. Transforming growth factor production by chemically transformed cells. , 1981, Cancer research.
[12] J. Wrana,et al. The Smad pathway. , 2000, Cytokine & growth factor reviews.
[13] P. Chambon,et al. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas , 1990, Nature.
[14] Y. Kaneda,et al. Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney , 1996, Nature Medicine.
[15] J. Dichgans,et al. Transforming growth factors beta(1) (TGF-beta(1)) and TGF-beta(2) promote glioma cell migration via Up-regulation of alpha(V)beta(3) integrin expression. , 2000, Biochemical and biophysical research communications.
[16] R. Iozzo. The Biology of the Small Leucine-rich Proteoglycans , 1999, The Journal of Biological Chemistry.
[17] Y Iwamoto,et al. A rapid in vitro assay for quantitating the invasive potential of tumor cells. , 1987, Cancer research.
[18] J. Dignam,et al. Structural characterization of the latent complex between transforming growth factor beta 1 and beta 1-latency-associated peptide. , 1996, The Biochemical journal.
[19] M. Weller,et al. Ezrin-Dependent Promotion of Glioma Cell Clonogenicity, Motility, and Invasion Mediated by BCL-2 and Transforming Growth Factor-β2 , 2001, The Journal of Neuroscience.
[20] M. Platten,et al. Malignant glioma biology: Role for TGF‐β in growth, motility, angiogenesis, and immune escape , 2001 .
[21] J. Dichgans,et al. N‐[3,4‐dimethoxycinnamoyl]‐anthranilic acid (tranilast) inhibits transforming growth factor‐β release and reduces migration and invasiveness of human malignant glioma cells , 2001, International journal of cancer.
[22] Z. Gokaslan,et al. In vitro inhibition of human glioblastoma cell line invasiveness by antisense uPA receptor , 1997, Oncogene.
[23] K. Miyazono,et al. Enhanced expression of transforming growth factor‐β and its type‐I and type‐II receptors in human glioblastoma , 1995, International journal of cancer.
[24] M. Abe,et al. Cell-associated activation of latent transforming growth factor-beta by calpain. , 1998, Journal of cellular physiology.
[25] M. Weller,et al. Caspase-dependent chemotherapy-induced death of glioma cells requires mitochondrial cytochrome c release. , 2001, Biochemical and biophysical research communications.
[26] A. Baker,et al. Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3 , 1999, British Journal of Cancer.
[27] A. Angelucci,et al. Osteoblast‐derived TGFβ‐1 modulates matrix degrading protease expression and activity in prostate cancer cells , 2000 .
[28] R. Herbst,et al. Transforming growth factor-beta 1 overexpression produces drug resistance in vivo: reversal by decorin. , 1997, In vivo.
[29] H. Ikeda,et al. Inhibitory effect of tranilast on activation and transforming growth factor beta 1 expression in cultured rat stellate cells. , 1996, Biochemical and biophysical research communications.
[30] M. Weller,et al. Molecular determinants of glioma cell migration and invasion. , 2001, Journal of neurosurgery.
[31] Y. Goto,et al. The effect of tranilast on experimental proliferative vitreoretinopathy , 1999, Graefe's Archive for Clinical and Experimental Ophthalmology.
[32] J. Massagué,et al. Transcriptional control by the TGF‐β/Smad signaling system , 2000 .
[33] G. Pilkington,et al. The effects of exogenous growth factors on matrix metalloproteinase secretion by human brain tumour cells , 1999, British Journal of Cancer.
[34] A Rimner,et al. Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblastoma. , 2001, Cancer research.
[35] L. Myeroff,et al. Mutation of the type II transforming growth factor-beta receptor is coincident with the transformation of human colon adenomas to malignant carcinomas. , 1998, Cancer research.
[36] G. Pilkington,et al. Control of human glioma cell growth, migration and invasion in vitro by transforming growth factor beta 1. , 1994, British Journal of Cancer.
[37] J. Uhm,et al. The role of integrins in the malignant phenotype of gliomas. , 1999, Frontiers in bioscience : a journal and virtual library.
[38] J. Tonn,et al. ECM‐mediated glioma cell invasion , 1998, Microscopy research and technique.
[39] J. Dichgans,et al. Decorin gene transfer-mediated suppression of TGF-β synthesis abrogates experimental malignant glioma growth in vivo , 1998, Gene Therapy.
[40] Y. St-Pierre,et al. In vitro expression of MMP-2 and MMP-9 in glioma cells following exposure to inflammatory mediators. , 1998, Biochimica et biophysica acta.
[41] T. Thompson,et al. Novel regulation of type IV collagenase (matrix metalloproteinase-9 and -2) activities by transforming growth factor-beta1 in human prostate cancer cell lines. , 1999, Molecular biology of the cell.
[42] K. Miyazono,et al. Transforming growth factor-beta 1, -beta 2, and -beta 3 secreted by a human glioblastoma cell line. Identification of small and different forms of large latent complexes. , 1992, The Journal of biological chemistry.
[43] 廣井 信,et al. ハムスター実験膵癌モデルにおけるN-[3,4-Dimethoxycinnamoyl]-Anthranilic Acid(Tranilast)の抗腫瘍効果 , 2002 .
[44] J. Tonn,et al. Effect of synthetic matrix‐metalloproteinase inhibitors on invasive capacity and proliferation of human malignant gliomas In vitro , 1999, International journal of cancer.
[45] T. Tsuzuki,et al. Neural cell adhesion molecule L1 in gliomas: correlation with TGF-beta and p53. , 1998, Journal of clinical pathology.
[46] R. Leduc,et al. Processing of Transforming Growth Factor 1 Precursor by Human Furin Convertase (*) , 1995, The Journal of Biological Chemistry.
[47] J. Massagué,et al. The transforming growth factor-beta family. , 1990, Annual review of cell biology.
[48] A. Strongin,et al. Matrix metalloproteinase-2 activation modulates glioma cell migration. , 1997, Journal of cell science.
[49] N. Nagy,et al. Human ex vivo carcinoma cells produce transforming growth factor β and thereby can inhibit lymphocyte functions in vitro , 1997, Cancer Immunology, Immunotherapy.
[50] Jian-ming Li,et al. Sp1, but not Sp3, functions to mediate promoter activation by TGF-beta through canonical Sp1 binding sites. , 1998, Nucleic acids research.
[51] O. Monni,et al. Identification and Characterization of a New Latent Transforming Growth Factor-β-binding Protein, LTBP-4* , 1998, The Journal of Biological Chemistry.
[52] M. Olman,et al. Up-regulation of urokinase and urokinase receptor genes in malignant astrocytoma. , 1995, The American journal of pathology.
[53] L. Liotta,et al. Metastatic potential correlates with enzymatic degradation of basement membrane collagen , 1980, Nature.
[54] T. Hada,et al. Excessive production of transforming growth-factor β1 can play an important role in the development of tumorigenesis by its action for angiogenesis: validity of neutralizing antibodies to block tumor growth , 1992 .
[55] J. Dichgans,et al. Predicting chemoresistance in human malignant glioma cells: The role of molecular genetic analyses , 1998, International journal of cancer.
[56] Erwin G. Van Meir,et al. Analysis of the p53 gene and its expression in human glioblastoma cells. , 1994, Cancer research.
[57] R. Hynes,et al. Thrombospondin-1 Is a Major Activator of TGF-β1 In Vivo , 1998, Cell.
[58] Adriano Fontana,et al. The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-β, T-cell apoptosis, and the immune privilege of the brain , 1995, Brain Research Reviews.
[59] J. Dichgans,et al. BCL‐2 promotes migration and invasiveness of human glioma cells , 1998, FEBS letters.
[60] A. Angelucci,et al. Osteoblast‐derived TGF‐β1 modulates matrix degrading protease expression and activity in prostate cancer cells , 2000, International journal of cancer.
[61] N. Kaminski,et al. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. , 1999, Cell.
[62] K. Schlingensiepen,et al. Effects of Transforming Growth Factor‐β1 on Collagen Synthesis, Integrin Expression, Adhesion an Invasion of Glioma Cells , 1995 .
[63] M. Abe,et al. Cell‐associated activation of latent transforming growth factor‐β by calpain , 1998 .
[64] M. Czyz,et al. Selective Sp1 and Sp3 binding is crucial for activity of the integrin alphaV promoter in cultured endothelial cells. , 1999, European journal of biochemistry.